Quality of Life with Pregabalin Plus Duloxetine versus Pregabalin Plus Amitriptyline in Chronic Lumbar Radiculopathy
Naogaon Medical College Journal · 10.11.2026 · 3 (2) · 67-76
DOI: 10.70818/nmcj.v03i02.092 ↗Kurz gefasst
Fachartikel in der Zeitschrift Naogaon Medical College Journal, online erschienen am 10.11.2026. Verfasst von Sabrina Masrufa Khanam und 4 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Health-related quality of life (HRQoL) is an important patient-centered outcome in chronic low back pain (CLBP) with radiculopathy, as pain intensity alone does not fully reflect physical, emotional, and functional impairment. This study compared HRQoL outcomes between pregabalin–duloxetine and pregabalin–amitriptyline combination therapy in these patients.
Methods
This prospective longitudinal study was conducted at Dhaka Medical College Hospital from July 2024 to September 2025. Seventy-six adults with CLBP and radiculopathy of at least three months’ duration were allocated sequentially to Group I (pregabalin–duloxetine, n=38) or Group II (pregabalin–amitriptyline, n=38). HRQoL was assessed using selected response categories of the Short Form-36 (SF-36) Health Survey at baseline and at weeks 4, 8, 12, and 24. Adverse effects were recorded at each follow-up visit.
Results
Both regimens improved selected SF-36 response categories over 24 weeks. At week 24, Group I showed numerically favorable outcomes in general health perception (89.0% vs. 84.2% excellent), role limitations due to physical health (81.6% vs. 71.1% not limited), and mental health (92.1% vs. 78.9% not downhearted) compared with Group II. Pain relief was similar, with 92.1% in each group reporting no bodily pain at week 24, and 76.3% in both groups reported full energy all of the time. Group I had a more favorable tolerability profile, with 68.4% reporting no adverse effects compared with 2.6% in Group II.
Conclusions
Both pregabalin–duloxetine and pregabalin–amitriptyline improved HRQoL among patients with CLBP and radiculopathy. Pregabalin–duloxetine showed numerically better HRQoL responses and markedly fewer adverse effects, suggesting better tolerability.
Zitieren
APA
Khanam, S. M., Sarker, S. K., Mullick, A. R., Anwar, S. N. M. R., & Chowdhury, M. H. (2026). Quality of Life with Pregabalin Plus Duloxetine versus Pregabalin Plus Amitriptyline in Chronic Lumbar Radiculopathy. Naogaon Medical College Journal, 3(2), 67-76. https://doi.org/10.70818/nmcj.v03i02.092
Vancouver
Khanam SM, Sarker SK, Mullick AR, Anwar SNMR, Chowdhury MH. Quality of Life with Pregabalin Plus Duloxetine versus Pregabalin Plus Amitriptyline in Chronic Lumbar Radiculopathy. Naogaon Medical College Journal. 2026;3(2):67-76. doi:10.70818/nmcj.v03i02.092
BibTeX
@article{Khanam2026,
author = {Khanam, Sabrina Masrufa and Sarker, Sujit Kumar and Mullick, Ashekur Rahman and Anwar, Shah Niaz MD Rubaid and Chowdhury, Md Hashib},
title = {Quality of Life with Pregabalin Plus Duloxetine versus Pregabalin Plus Amitriptyline in Chronic Lumbar Radiculopathy},
journal = {Naogaon Medical College Journal},
year = {2026},
volume = {3},
number = {2},
pages = {67--76},
doi = {10.70818/nmcj.v03i02.092}
}
EUVIMED